To Vestor and Brad:
Once again, my intention was not to start discussion on CE9.1 or other Idec products.
Brad, I am on IDPH for over two years. Anyway thanks for input.
Vestor, IMO the main questions is not only on side-effects in long-term monoclonal therapy! Long-term therapeutic effectiveness of any MA is main question. Can MA sustain therapeutic effect and do not trigger antigen immune response (which neutralize drug)? Future will answer on this question.
Regards the current MA trials for RA:
1. CE9.1 ; Response of ~50% versus 20% in placebo. Is this excellent results?
2. Cen-TNF (CNTO); Response of ~80% in combination with methotrexate versus 20% for methothexate alone (+ placebo), final P II data will be known in next RA meeting.
3. sTNFr (IMNX); Response of ~80% after single therapy versus 14% in placebo, upper respiratory infections as side effects (36% according to last press release).
4. IL-1 (AMGN); Response of 43% versus 27 in placebo, positive effects on bone destruction.
Brad, when somebody comments on competitors, normally will be presenting data, not who is or who is not "excited" about. Every company is exited about its products, as every parents excited about its kids.
Also, CE9.1 is at beginning of the P III trials (first P III, out of min. two), not approaching the finish line.
Regards the ISIS 2302, when data for P II are known, we can compared with other.
I will close this discussion, and wish you all good luck.
mz
|
